A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY plus E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx plus ) metastatic NSCLC.

被引：23

作者：

Camidge, D. Ross

Moran, Teresa

Demedts, Inge

Grosch, Heidrun

Di Mercurio, Jean-Pierre

Mileham, Kathryn Finch

Molina, Julian R.

Vidal, Oscar Juan

Bepler, Gerold

Goldman, Jonathan Wade

Lewanski, Conrad

Park, Keunchil

Wallin, Johan

Wijayawardana, Sameera R.

Wang, Xuejing Aimee

Wacheck, Volker

Smit, Egbert F.

机构：

[1] Univ Colorado, Aurora, CO USA

[2] Catalan Inst Oncol, Badalona, Spain

[3] AZ Delta, Roeselare, Belgium

[4] Thorax Klin, Heidelberg, Germany

[5] Hop Arnaud Villeneuve, Montpellier, France

[6] Levine Canc Inst, Charlotte, NC USA

[7] Mayo Clin, Rochester, MN USA

[8] Hosp Univ & Politecn La Fe, Valencia, Spain

[9] Karmanos Canc Inst, Detroit, MI USA

[10] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[11] Charing Cross Hosp, London, England

[12] Sungkyunkwan Univ, Innovat Canc Med Inst, Samsung Med Ctr, Sch Med, Seoul, South Korea

[13] Eli Lilly & Co, Indianapolis, IN 46285 USA

[14] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.9070

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9070

引用

页数：3